Medilabo RFP, Inc., headquartered in Japan with a US office in Boston, is a clinical-stage biopharmaceutical company focused on developing repurposed small molecules-based treatments to restore neuronal function and slow neurodegeneration. Medilabo aims to halt the progression of cognitive impairment and reverse the course of neurological diseases with its novel multi-modal mechanisms ofaction. Medilabo is currently advancing its lead candidates, ML1707 and ML1808, the novel approaches of repurp